BioSenic S.A. (BIOS.BR)
EUR 0.01
(-5.71%)
EUR 0.01
(-5.71%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 15.57 Million EUR | -1.29% |
| 2022 | 15.77 Million EUR | -20.13% |
| 2021 | 19.75 Million EUR | 68.53% |
| 2020 | 11.72 Million EUR | 6.5% |
| 2019 | 11 Million EUR | 7.4% |
| 2018 | 10.24 Million EUR | -2.88% |
| 2017 | 10.55 Million EUR | -5.52% |
| 2016 | 11.16 Million EUR | 10.36% |
| 2015 | 10.11 Million EUR | 73.66% |
| 2014 | 5.82 Million EUR | 15.34% |
| 2013 | 5.05 Million EUR | 22.77% |
| 2012 | 4.11 Million EUR | 33.17% |
| 2011 | 3.09 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 22.6 Million EUR | 45.16% |
| 2024 Q2 | 22.6 Million EUR | 0.0% |
| 2023 Q4 | 15.57 Million EUR | -4.69% |
| 2023 Q3 | 16.34 Million EUR | 4.1% |
| 2023 FY | 15.57 Million EUR | -1.29% |
| 2023 Q1 | 15.69 Million EUR | -0.51% |
| 2023 Q2 | 15.69 Million EUR | 0.0% |
| 2022 Q4 | 15.77 Million EUR | -0.02% |
| 2022 FY | 15.77 Million EUR | -20.13% |
| 2022 Q2 | 15 Million EUR | 0.0% |
| 2022 Q3 | 15.77 Million EUR | 5.17% |
| 2021 Q2 | 11.71 Million EUR | 0.0% |
| 2021 Q4 | 19.75 Million EUR | 0.0% |
| 2021 FY | 19.75 Million EUR | 68.53% |
| 2020 FY | 11.72 Million EUR | 6.5% |
| 2020 Q4 | 11.72 Million EUR | 0.0% |
| 2020 Q2 | 14.93 Million EUR | 0.0% |
| 2019 Q4 | 11 Million EUR | 0.0% |
| 2019 Q2 | 12.75 Million EUR | 0.0% |
| 2019 FY | 11 Million EUR | 7.4% |
| 2018 Q2 | 9.73 Million EUR | 0.0% |
| 2018 FY | 10.24 Million EUR | -2.88% |
| 2018 Q4 | 10.24 Million EUR | 0.0% |
| 2017 Q4 | 10.55 Million EUR | 0.0% |
| 2017 FY | 10.55 Million EUR | -5.52% |
| 2017 Q2 | 10.43 Million EUR | 0.0% |
| 2016 Q2 | 10.1 Million EUR | 0.0% |
| 2016 Q4 | 11.16 Million EUR | 0.0% |
| 2016 FY | 11.16 Million EUR | 10.36% |
| 2015 Q2 | 5.44 Million EUR | 0.0% |
| 2015 Q4 | 10.11 Million EUR | 0.0% |
| 2015 FY | 10.11 Million EUR | 73.66% |
| 2014 Q4 | 5.82 Million EUR | 14.66% |
| 2014 Q3 | 5.08 Million EUR | 0.0% |
| 2014 FY | 5.82 Million EUR | 15.34% |
| 2013 FY | 5.05 Million EUR | 22.77% |
| 2013 Q4 | 5.05 Million EUR | 0.0% |
| 2012 FY | 4.11 Million EUR | 33.17% |
| 2011 FY | 3.09 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -1314.441% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 65.159% |
| Adocia SA | 4.54 Million EUR | -243.018% |
| Aelis Farma SA | 2.04 Million EUR | -660.4% |
| Biophytis S.A. | 3.11 Million EUR | -400.579% |
| Advicenne S.A. | 15.89 Million EUR | 2.032% |
| genOway Société anonyme | 5.51 Million EUR | -182.155% |
| IntegraGen SA | 642.28 Thousand EUR | -2324.643% |
| Medesis Pharma S.A. | 1.2 Million EUR | -1197.75% |
| Neovacs S.A. | 650 Thousand EUR | -2295.846% |
| NFL Biosciences SA | 39.2 Thousand EUR | -39624.001% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -257.465% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -694.407% |
| Sensorion SA | 1.24 Million EUR | -1154.965% |
| Theranexus Société Anonyme | 2.46 Million EUR | -532.864% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -299.513% |
| TheraVet SA | 1 Million EUR | -1456.368% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -125.5% |
| argenx SE | 15.35 Million EUR | -1.426% |
| Celyad Oncology SA | 902 Thousand EUR | -1626.497% |
| DBV Technologies S.A. | 4.52 Million USD | -244.079% |
| Galapagos NV | 4.94 Million EUR | -214.988% |
| Genfit S.A. | 62.25 Million EUR | 74.984% |
| GeNeuro SA | 6.49 Million EUR | -139.869% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -4427.035% |
| Innate Pharma S.A. | 30.6 Million EUR | 49.119% |
| Inventiva S.A. | 25.61 Million EUR | 39.206% |
| MaaT Pharma SA | 5.42 Million EUR | -187.06% |
| MedinCell S.A. | 52.8 Million EUR | 70.506% |
| Nanobiotix S.A. | 41.66 Million EUR | 62.619% |
| Onward Medical N.V. | 16.3 Million EUR | 4.495% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -351.311% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 56.142% |
| Oxurion NV | 117 Thousand EUR | -13210.256% |
| Pharming Group N.V. | 123.65 Million EUR | 87.406% |
| Poxel S.A. | 40.14 Million EUR | 61.206% |
| GenSight Biologics S.A. | 1.04 Million EUR | -1385.973% |
| Transgene SA | 17 Thousand EUR | -91505.882% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.459% |
| Valneva SE | 132.76 Million EUR | 88.271% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |